Acuvail

DRUG2 trials

Sponsors

Vanderbilt University, Retina Vitreous Associates of Florida

Conditions

Age-related Macular DegenerationCentral Retinal Vein OcclusionDiabetic Macular EdemaInflammation

Phase 1

The Role of Prostaglandins in the Progression of Diabetic Retinopathy

WithdrawnNCT01609881

Vanderbilt UniversityInflammation

Start: 2012-03-31End: 2016-10-19Updated: 2017-02-23

Unknown Phase

Anesthesia Preference for Intravitreal Injection: Topical or Subconjunctival

CompletedNCT01640171

Retina Vitreous Associates of FloridaAge-related Macular Degeneration, Central Retinal Vein Occlusion, Diabetic Macular Edema

Start: 2012-07-31End: 2013-10-31Updated: 2014-04-21

Related Papers

Reduction of Interleukin 8 and Platelet-Derived Growth Factor Levels by Topical Ketorolac, 0.45%, in Patients With Diabetic Retinopathy

JAMA Ophthalmology2013-12-1332 citations

Reduction of Vitreous Prostaglandin E<sub>2</sub>Levels After Topical Administration of Ketorolac 0.45%

JAMA Ophthalmology2013-11-2125 citations

Increased prostaglandin E2 (PGE2) levels in proliferative diabetic retinopathy, and correlation with VEGF and inflammatory cytokines.

2012-08-27103 citations